申请人:Bristol-Myers Squibb Company
公开号:US20160176871A1
公开(公告)日:2016-06-23
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
这项发明通常涉及调节TGFβR-1和TGFβR-2活性的化合物,包含这些化合物的药物组合物以及利用该发明的化合物治疗增殖性疾病和失调凋亡疾病(如癌症)的方法。